Safety and efficacy of intralesional bleomycin for keloids and hypertrophic scars: A systematic review and meta‐analysis

Shun Jie You,Si Li,Chen Ming Hu,Fang Yu Zhong,Shi Han Gan,Yan Cai,Xiao Yan Xiang
DOI: https://doi.org/10.1111/jocd.16447
2024-08-31
Journal of Cosmetic Dermatology
Abstract:Background Bleomycin, originally an antitumor drug, was explored as a pathological scar treatment in the mid‐1990s. However, its efficacy and safety profile varies among individuals. Aims This study aimed to assess topical bleomycin's efficacy and safety in treating hypertrophic scars and keloids. Methods We reviewed randomized controlled trials (RCTs) and controlled clinical trials (CCTs) published in English, comparing intralesional bleomycin to placebos or common intralesional scar treatments. Primary outcomes included percentage change in scar improvement, pigmentation, recurrence, atrophy, pain, telangiectasia, ulceration, patient self‐assessment, and observer assessment (>50%). Results Six trials met the criteria. Bleomycin significantly improved scar reduction compared to triamcinolone (p
dermatology
What problem does this paper attempt to address?